Mobocertinib (TAK-788) is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions.
DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents, Kd value is 3.46 nM for native μ-OPR.
DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents, Kd value is 3.46 nM for native μ-OPR.
Namodenoson (also known as 2-Cl-IB-MECA and CF-102) is an orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist (Ki=0.33 nM) with potential antineoplastic activity.
Namodenoson (also known as 2-Cl-IB-MECA and CF-102) is an orally bioavailable, synthetic, highly selective adenosine A3 receptor (A3AR) agonist (Ki=0.33 nM) with potential antineoplastic activity.
Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and l-glutamate-gated chloride channels (GluCls).
Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and l-glutamate-gated chloride channels (GluCls).
AZ-33 (LDHA-IN-4) is a potent lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.5 μM.
AZ-33 (LDHA-IN-4) is a potent lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.5 μM.
ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, it potently inhibited the interactions between a SMAC-derived peptide and the BIR3 domains of XIAP (BIR3-XIAP) and cIAP1 (BIR3-cIAP1) with IC50 values less than 40 and 12 nmol/L, respectively.